GURUFOCUS.COM » STOCK LIST » USA » NYSE » Bausch Health Companies Inc (NYSE:BHC) » Definitions » ROCE %
Switch to:

Bausch Health ROCE %

: 4.73% (As of Jun. 2022)
View and export this data going back to 1994. Start your Free Trial

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Bausch Health's annualized ROCE % for the quarter that ended in Jun. 2022 was 4.73%.

Bausch Health ROCE % Historical Data

The historical data trend for Bausch Health's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch Health Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROCE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 -7.98 -0.80 2.23 1.60

Bausch Health Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
ROCE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.91 9.38 6.09 4.64 4.73

Bausch Health ROCE % Calculation

Bausch Health's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2021 )  (A: Dec. 2020 )(A: Dec. 2021 )
=402/( ( (31199 - 4913) + (29202 - 5198) )/ 2 )
=402/( (26286+24004)/ 2 )
=402/25145
=1.60 %

Bausch Health's ROCE % of for the quarter that ended in Jun. 2022 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2022 )  (Q: Mar. 2022 )(Q: Jun. 2022 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2022 )  (Q: Mar. 2022 )(Q: Jun. 2022 )
=1124/( ( (29090 - 4774) + (28171 - 4997) )/ 2 )
=1124/( ( 24316 + 23174 )/ 2 )
=1124/23745
=4.73 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2022) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bausch Health  (NYSE:BHC) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Bausch Health ROCE % Related Terms

Thank you for viewing the detailed overview of Bausch Health's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bausch Health Business Description

Bausch Health logo
Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bausch Health Companies Inc (NYSE:BHC) » Definitions » ROCE %
Comparable Companies
XCNQ:VRNO TSX:WEED TSX:CRON XCNQ:GTII XCNQ:CL XCNQ:TRUL NEOE:CCHW XCNQ:TER TSX:GUD XCNQ:AAWH.U NYSE:ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA NYSE:CTLT SHSE:600196 TSE:4507 SZSE:000538 TSE:4523
Traded in Other Exchanges
BHC:Mexico 0QYW:UK BVF:Germany BVF:Germany BHC:Canada
Address
2150 Saint Elzear Boulvard West, Laval, QC, CAN, H7L 4A8
Website
https://www.bauschhealth.com
Bausch Health Companies Inc develop, manufacture and market, primarily in the therapeutic areas of eye-health, gastroenterology and dermatology, a broad range of branded pharmaceuticals, generic and branded generic pharmaceuticals, over-the-counter products and medical devices, which are marketed directly or indirectly in approximately 100 countries. The company's business segments are Bausch + Lomb, Salix, International Rx, Ortho Dermatologics and Diversified Products with maximum revenue from Bausch + Lomb segment.
Executives
Carson Seana officer: EVP, General Counsel 400 SOMERSET CORPORATE BLVD BRIDGEWATER NJ 08807
Vadaketh Tom George officer: EVP, Chief Financial Officer 1727 JOCKEYS WAY YARDLEY PA 19067
Mulligan Richard director C/O ICAHN CAPITAL LP 767 FIFTH AVENUE, SUITE 4700 NEW YORK NY 10153
Munsch Frederick officer: SVP, Controller and CAO 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807
Gordon Joseph F officer: Pres&Co-Head Bausch&Lomb/Int'l 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807
Ackermann Christina officer: EVP AND GENERAL COUNSEL C/O BLCO 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807
Spurr Robert director, officer: U.S. President-Pharma Business C/O BAUSCH HEALTH COMPANIES INC. 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807
Eldessouky Sam officer: EVP & Chief Financial Officer C/O BAUSCH HEALTH COMPANIES INC. 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807
Miller Steven D director 16690 COLLINS AVENUE PH SUNNY ISLE BEACH FL 33160
Icahn Brett director C/O ICAHN ENTERPRISES L.P. 16690 COLLINS AVE., PH SUNNY ISLES FL 33160
Paulson John director 1133 AVENUE OF THE AMERICAS 33RD FLOOR NEW YORK NY 10036
Valueact Holdings Ii, L.p. director, other: See Remarks ONE LETTERMAN DRIVE BUILDING D, FOURTH FLOOR SAN FRANCISCO CA 94129
Von Eschenbach Andrew C. director BAUSCH HEALTH COMPANIES INC. 400 SOMERSET CORPORATE BLVD. BRIDGEWATER NJ 08807
Mckenna Mark C. officer: President, Salix 400 SOMERSET CORPORATE BOULEVARD BRIDGEWATER NJ 08807
Humphries William D. officer: EVP, COMPANY GROUP CHAIRMAN C/O STRATA SKIN SCIENCES, INC. 5 WALNUT GROVE DRIVE SUITE 140 HORSHAM PA 19044

Bausch Health Headlines

From GuruFocus

Bausch Health Announces It Is Seeking To Refinance Its Existing Credit Agreement And Conditional Redemption Of Existing Notes - These Steps Will Enable Bausch + Lomb IPO And Facilitate Full Separation

By PRNewswire 01-18-2022

Bausch + Lomb Corporation Files Registration Statement and Preliminary Prospectus for Proposed Initial Public Offering

By PRNewswire 01-13-2022

New Data on Cost Impact of Treating Opioid-Induced Constipation (OIC) with FDA-Approved Medications, Including Salix's RELISTOR® Subcutaneous Injection (Methylnaltrexone Bromide), in The Emergency Department Is Published in Advances In Therapy

By PRNewswire 03-24-2022

Permian Investment Partners, LP Buys Bausch Health Inc, APi Group Corp, Controladora Vuela Compania de Aviacion SAB de CV, Sells NRG Energy Inc, Devon Energy Corp, KBR Inc

By insider 02-18-2022

Dr. Yehia Hashad Will Join Bausch + Lomb Corporation as Executive Vice President of Research & Development and Chief Medical Officer

By PRNewswire 01-20-2022

Salix and Colon Cancer Coalition Join Forces for 'Faces of Blue' Story Series to Raise Awareness of Colorectal Cancer Screenings

By PRNewswire 03-01-2022

BAUSCH + LOMB AND PREVENT BLINDNESS LAUNCH ANNUAL AMD AWARENESS MONTH CAMPAIGN TO EDUCATE PATIENTS

By PRNewswire 02-01-2022

Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis

By PRNewswire 03-28-2022

Bausch Health Announces Launch Of Private Offering Of Senior Secured Notes

By PRNewswire 01-31-2022

Bausch Health Will Provide Business And Strategic Update At The 40th Annual J.P. Morgan Healthcare Conference

By PRNewswire 01-11-2022

Other Sources

$BHC - Bausch Health Companies Inc. 2021 Q4 - Results - Earnings Call Presentation. Bausch Health Companies Inc 2021 Q4 Results Earnings Call Presentation

By Seekingalpha 2022-02-23

Bausch Health (BHC) Dips More Than Broader Markets: What You Should Know

By Zacks 2022-04-05

Bausch Health (BHC) Beats Q4 Earnings Estimates

By Zacks 2022-02-23

Analysts Offer Insights on Healthcare Companies: Provention Bio (PRVB), Bausch Health Companies (BHC) and Sangamo Biosciences (SGMO)

By tipranks.com 2022-02-27

Anthem's (ANTM) Q4 Earnings Beat Estimates, Improve Y/Y

By Zacks 2022-01-26

Bausch's (BHC) Q4 Earnings Beat Estimates, Revenues Miss

By Zacks 2022-02-24

UnitedHealth (UNH) Q4 Earnings Beat Estimates, Improve Y/Y

By Zacks 2022-01-19

Bausch Health (BHC) Stock Sinks As Market Gains: What You Should Know

By Zacks 2022-03-15

Is a Beat in Store for HCA Healthcare's (HCA) Q4 Earnings?

By Zacks 2022-01-24

Bausch Health (BHC) Gains But Lags Market: What You Should Know

By Zacks 2022-01-31

Bausch Health (BHC) Stock Moves -0.56%: What You Should Know

By Zacks 2022-03-30

Bausch Health (BHC) Dips More Than Broader Markets: What You Should Know

By Zacks 2022-02-14

$BHC - Bausch And Lomb Spinoff Worth More Than All Of Bausch Health. Bausch And Lomb Spinoff Worth More

By Seekingalpha 2022-01-31

Bausch Health (BHC) Dips More Than Broader Markets: What You Should Know

By Zacks 2022-03-10

Bausch Health Swings to Profit in Q4

By tipranks.com 2022-02-23

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)